AbbVie
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world. Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months. There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being
Inclusion Criteria: * Eligibility for Foslevodopa/Foscarbidopa (LDp/CDp) therapy in accordance with approved local label in the participating country and local reimbursement regulations, if applicable * A diagnosis of levodopa-responsive idiopathic Parkinson's Disease (PD) * Adult male or female between 18 and 80 years of age * Disease duration (time since diagnosis) \<10 years * Time since motor fluctuations ≤3 years * H\&Y Stage \<3 in best "on" * "off" time of 2.5-6 hours per day * Naïve to LDp/CDp * Treatment has been optimized with oral/transdermal PD medication in the opinion of the Inv…